Mediastinal staging in non-small-cell lung cancer

Area of Science:

• Oncology
• Medical Diagnostics
• Health Economics

Background:

• Accurate staging of mediastinal involvement is crucial for non-small cell lung cancer (NSCLC) treatment planning.
• Current diagnostic strategies for mediastinal staging in NSCLC vary, impacting cost and patient outcomes.
• Decision analysis provides a framework for evaluating and comparing complex diagnostic pathways.

Purpose of the Study:

• To compare the cost-effectiveness and impact on life expectancy of different diagnostic strategies for mediastinal staging in NSCLC.
• To identify the optimal diagnostic approach for evaluating mediastinal lymph node involvement in NSCLC patients.
• To inform clinical guidelines on mediastinal staging for non-small cell lung cancer.

Main Methods:

• Decision analysis modeling was employed to compare various diagnostic strategies.
• Strategies included computed tomography (CT), mediastinoscopy, and bronchoscopy with transbronchial needle aspiration (TBNA), used individually and in combination.
• Model inputs encompassed a range of prior probabilities, test characteristics, and healthcare charges.

Main Results:

• All evaluated diagnostic strategies resulted in comparable patient life expectancies.
• Strategies utilizing bronchoscopy and TBNA, either alone or with CT, were consistently the least expensive.
• Cost-effectiveness was maintained across diverse assumptions regarding disease prevalence and test performance.

Conclusions:

• Diagnostic strategies for mediastinal staging in NSCLC that incorporate bronchoscopy and TBNA are preferable due to their lower cost.
• The findings suggest that less invasive and more targeted approaches can achieve comparable outcomes at a reduced financial burden.
• Optimizing diagnostic pathways in NSCLC can lead to significant healthcare savings without compromising patient survival.